证券代码：000650 证券简称：仁和药业 公告编号：2023-027 仁和药业股份有限公司 关于参加 2023 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，仁和药业股份有限公司 (以下简称 "公司")将参加由江西证监局、江西省上市公司协会与深圳市全景网络有限公 司联合举办的 "2023年江西辖区上市公司投资者集体接待日活动"，现将有关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可以登录"全景路演"网站 (http://rs.p5w.net)或关注微信公众号：全景财经，或下载全景路演APP，参与 本次互动交流，活动时间为2023年5月19日（周五） 14:30-17:00。 届时公司高管将通过网络在线交流形式与投资者就2022年年报、公司治理、 发展战略、经营状况、融资计划、股权激励和可持续发展等投资者关注的问题进 行沟通。欢迎广大投资者积极参与。 特此公告 仁和药业股份有限公司 董事会 二〇二三年五月十五日 ...

证券代码：000650 证券简称：仁和药业 仁和药业股份有限公司 投资者关系活动记录表 | 线城市，而仁和的大健康产品客观上更趋向三四线城市，如何解决 | | --- | | 产品市场与渠道错位的问题？ | | 答:1、回复：公司2023年第一季度营收为13.56亿，同比增长 | | 3.39%。主要是一季度受公共突发事件放开管控影响，公司药品板 | | 块增长明显，但大健康板块拖累公司一季度营收。2023年公司目标 | | 任务计划已落实下达各子公司，相信公司2023年一定会比2022年 | | 好。谢谢！ 2、回复：公司制订了严格的质量控制体系，并根据 | | 《中华人民共和国药品管理法》《中华人民共和国药品生产质量管 | | 理规范》和《中华人民共和国药品经营质量管理规范》制定了《供 | | 应生产销售内部控制实施细则》《质量管控制度》《异常物料处理 | | 管理规定》等一整套比较完备的制度，通过了GSP、GMP的认证，并 | | 在日常经营过程中，严格按照相关制度的规定执行。公司实行各级 | | 质量责任制，质量管理部门负责人主要是在公司总经理办公室领导 | | 下，行使质量管理职能，认真贯彻执行《药 ...

Revenue and Profit - Revenue for Q1 2023 was CNY 1,355,800,163.83, an increase of 3.39% compared to CNY 1,311,390,192.42 in the same period last year[6] - Net profit attributable to shareholders was CNY 182,299,215.54, representing a growth of 17.09% from CNY 155,695,612.25 year-on-year[6] - The net profit after deducting non-recurring gains and losses was CNY 175,174,269.85, up 23.34% from CNY 142,021,663.72 in the previous year[6] - Basic earnings per share increased to CNY 0.1302, up 17.09% from CNY 0.1112 year-on-year[6] - Operating profit for the first quarter was CNY 296,051,840.96, compared to CNY 257,635,696.12 in the previous year, reflecting an increase of about 14.9%[28] - Net profit attributable to the parent company was CNY 182,299,215.54, up from CNY 155,695,612.25 year-over-year, indicating a growth of approximately 17.1%[28] Cash Flow - The net cash flow from operating activities was -CNY 145,786,103.21, a decline of 48.06% compared to -CNY 98,462,253.02 in the same period last year[6] - Cash inflow from operating activities totaled 1,129,611,784.19 yuan, up from 1,069,263,178.46 yuan in Q1 2022, indicating a growth of about 5.6%[32] - Cash outflow from operating activities was 1,275,397,887.40 yuan, compared to 1,167,725,431.48 yuan in the previous year, reflecting an increase of approximately 9.2%[32] - Cash inflow from investment activities was 1,273,240,473.57 yuan, down from 1,452,261,905.90 yuan in Q1 2022, a decrease of about 12.3%[35] - Cash outflow from investment activities increased to 2,924,946,861.05 yuan from 2,425,428,238.45 yuan, marking a rise of approximately 20.6%[35] - Net cash flow from investment activities was -1,651,706,387.48 yuan, compared to -973,166,332.55 yuan in the same quarter last year, indicating a significant decline[35] - The ending balance of cash and cash equivalents was 1,027,984,204.90 yuan, down from 1,288,794,795.96 yuan year-over-year, a decrease of about 20.2%[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,674,834,465.36, a slight increase of 0.57% from CNY 7,631,643,912.76 at the end of the previous year[6] - Total liabilities decreased from CNY 1,209,855,727.22 to CNY 1,033,752,161.57, a reduction of approximately 14.6%[25] - The company's cash and cash equivalents decreased from CNY 2,825,476,695.59 at the beginning of the year to CNY 1,027,984,204.90 at the end of the reporting period[19] - The total current assets decreased from CNY 4,580,859,200.27 to CNY 4,503,672,685.49[19] - The company's other non-current financial assets increased from CNY 536,405,208.66 to CNY 621,323,838.80[19] Shareholder Information - Shareholders' equity attributable to the parent company was CNY 5,923,088,209.67, reflecting a growth of 3.18% from CNY 5,740,788,994.13 at the end of last year[6] - Total number of common shareholders at the end of the reporting period was 154,479[15] - The company has a notable shareholder concentration, with the top shareholder holding 23.24% of the shares[15] - The total number of preferred shareholders at the end of the reporting period was not specified, but the top 10 shareholders' details were provided[19] Research and Development - Research and development expenses decreased by 45.47% to CNY 7,684,761.30 from CNY 14,092,315.49 in the same period last year[11] - Research and development expenses for the quarter were CNY 7,684,761.30, down from CNY 14,092,315.49, a decrease of about 45.5%[26] Accounts Receivable and Inventory - The company reported a significant increase in receivables, with accounts receivable rising by 70.94% to CNY 595,350,415.36 from CNY 348,270,958.86 year-on-year[11] - Accounts receivable rose from CNY 348,270,958.86 to CNY 595,350,415.36, indicating a growth of approximately 70.9%[19] - Inventory decreased slightly from CNY 457,735,527.05 to CNY 443,724,549.60[19] Tax and Other Expenses - The company reported a tax expense of CNY 75,847,801.25, compared to CNY 62,942,981.47 in the previous year, an increase of approximately 20.5%[28] Other Information - The company reported a cash inflow from sales of goods and services of 1,102,861,186.52 yuan, compared to 1,049,759,062.30 yuan in the previous year, an increase of approximately 5.1%[32] - The company did not report any significant new product launches or market expansions during this quarter[36]

Financial Performance - The company's operating revenue for 2022 was ¥5,153,215,069.28, an increase of 4.41% compared to ¥4,935,755,208.61 in 2021[22]. - The net profit attributable to shareholders for 2022 was ¥574,441,773.76, a decrease of 13.62% from ¥665,024,502.45 in 2021[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥502,054,608.78, down 18.14% from ¥613,312,354.33 in 2021[22]. - The cash flow from operating activities increased by 63.30% to ¥1,269,978,522.06 in 2022, compared to ¥777,717,530.50 in 2021[22]. - The total assets at the end of 2022 were ¥7,631,643,912.76, reflecting a growth of 10.48% from ¥6,907,891,889.07 at the end of 2021[22]. - The basic earnings per share for 2022 were ¥0.41, a decrease of 14.58% from ¥0.48 in 2021[22]. - The weighted average return on equity for 2022 was 10.42%, down from 12.80% in 2021[22]. - The company reported a quarterly revenue of ¥1,307,434,536.12 in Q4 2022, with a net profit of ¥117,334,334.29 attributable to shareholders[26]. - The company recognized non-recurring gains of ¥72,387,164.98 in 2022, compared to ¥51,712,148.12 in 2021[29]. - In 2022, the company achieved total revenue of CNY 5.15 billion, a year-on-year increase of 4.41%[59]. - The net profit attributable to the parent company was CNY 574 million, representing a decrease of 13.62% compared to the previous year[59]. - Revenue from the pharmaceutical sector (including health-related products) was CNY 5.07 billion, accounting for 98.48% of total revenue, with a year-on-year growth of 4.82%[60]. - Health-related products revenue increased by 19.31% to CNY 1.35 billion, representing 26.24% of total revenue[60]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares to all shareholders, based on a total of 1,399,938,234 shares[3]. - The total cash dividend accounted for 100% of the profit distribution amount, with the distributable profit for the year being approximately 1.43 billion CNY[167]. - The company's board of directors balanced business development and shareholder returns when determining the profit distribution plan for 2022[168]. - The company has implemented a stable and proactive profit distribution policy, maintaining a cash dividend approach that meets the requirement of distributing at least 30% of the average distributable profit over the last three years[165]. Business Operations and Strategy - The company has undergone significant changes in its main business since 2006, including the acquisition of 100% equity in Jiangxi Renhe Pharmaceutical Co., Ltd[20]. - The company has multiple subsidiaries, including Jiangxi Renhe Pharmaceutical Co., Ltd and Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd, among others[12]. - The company aims to develop its health-related product segment to match the scale of its pharmaceutical segment within five years[40]. - The company is actively pursuing differentiation in niche markets to compete against larger pharmaceutical firms in the face of intense competition[38]. - The company is exploring market expansion opportunities within the growing health industry[45]. - The company is focusing on the development of new products and technologies, with an investment of 191.8 million yuan in research and development initiatives[89]. - The company plans to enhance production quality and optimize production processes to meet the 2023 economic targets[109]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with a budget of 500 million RMB for potential acquisitions[140]. Market and Industry Trends - The pharmaceutical industry in China is experiencing stable growth, driven by increasing health awareness and rising disposable income among the population[33]. - The pharmaceutical industry is a key focus of China's "Made in China 2025" initiative, with significant government support leading to an enhanced industry status[35]. - By 2050, the elderly population in China is projected to reach one-third of the total population, driving increased demand for pharmaceuticals[36]. - The domestic market for innovative drugs is expected to grow rapidly, with significant revenue potential compared to generic drugs[37]. - The health industry in China is projected to exceed 8 trillion RMB by 2020 and reach 16 trillion RMB by 2030, driven by aging population and increased health awareness[45]. Research and Development - The company has invested in research and development, enhancing its innovation capabilities and establishing partnerships with leading research institutions[57]. - R&D investment amounted to ¥51,422,817.77 in 2022, a decrease of 3.04% compared to ¥53,036,862.52 in 2021[72]. - The proportion of R&D investment to operating revenue was 1.00% in 2022, down from 1.07% in 2021[72]. - The number of R&D personnel decreased by 10.74% to 241 in 2022 from 270 in 2021[72]. - The company has obtained drug registration certificates for several new products, including tadalafil tablets and sildenafil citrate tablets, which are expected to support future growth[71]. - The company is currently conducting preclinical studies for multiple new drug projects, indicating ongoing investment in product development[71]. Regulatory and Compliance - The regulatory environment is becoming increasingly stringent, with policies aimed at enhancing compliance and market standardization[38]. - The company emphasizes strict quality control measures and has developed comprehensive internal control systems to mitigate risks related to product safety[56]. - The company has established a labor contract system in compliance with national labor laws[162]. - The company adheres to strict governance practices, ensuring compliance with laws and regulations while maintaining transparency and accountability in decision-making[119]. - The company has maintained effective internal control over financial reporting, with no significant deficiencies identified as of the evaluation report date[185]. Environmental Responsibility - The company has invested 2,364,856.41 CNY in environmental governance and protection, and paid 36,097.68 CNY in environmental protection tax[199]. - The wastewater treatment system has a designed capacity of 1,500 tons per day, processing wastewater from the raw material and formulation workshops[196]. - The company has implemented a clean fuel switch in the boiler workshop from biomass fuel to natural gas since June 2017[197]. - The company achieved compliance with emission standards for wastewater and waste gas as verified by third-party monitoring[197]. - The company has taken measures to reduce carbon emissions by optimizing production schedules and reducing boiler operation time[200]. Corporate Governance - The company has a well-defined corporate governance structure, with clear roles for the shareholders' meeting, board of directors, management, and supervisory board[177]. - The company has established an independent financial department and accounting system, allowing for autonomous financial decision-making without interference from the controlling shareholder[128]. - The company has confirmed that there are no issues related to illegal guarantees or major shareholder fund occupation[190]. - The company has established a special working group led by the chairman to enhance corporate governance and compliance with regulations[189]. Human Resources - The total number of employees at the end of the reporting period is 6,062, with 324 in the parent company and 5,738 in major subsidiaries[161]. - The company has implemented a salary policy based on market orientation, economic efficiency, job responsibilities, and performance metrics[162]. - The company emphasizes training for employees, particularly for sales and production staff, ensuring they undergo pre-job training[163]. - Talent development is crucial, with initiatives to build a high-quality talent pool and enhance employee capabilities to support the company's growth[118].

证券代码：000650 证券简称：仁和药业 公告编号：2023-022 仁和药业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 仁和药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日在巨潮 资讯网上披露了《2022 年度报告全文》及《2022 年度报告摘要》。为便于广大 投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 05 月 12 日（星期五）15:00-17:00 在"价值在线"（www.ir-online.cn）举办 仁和药业股份有限公司 2022 年度网上业绩说明会，与投资者进行沟通和交流， 广泛听取投资者的意见和建议。 一、说明会召开的时间、地点和方式 董事长 杨潇，总经理 黄武军，财务总监 彭秋林，独立董事 涂书田，董事 会秘书 姜锋（如遇特殊情况，参会人员可能进行调整）。 三、投资者参加方式： 投资者可于 2023 年 05 月 12 日 （ 星期 五 ） 15:00-17:00 通过 网 址 https://eseb. ...

编号：2014001 证券代码：000650 证券简称：仁和药业 仁和药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 川财证券有限责任公司 | ...

仁和药业股份有限公司 2022 年第三季度报告 证券代码：000650 证券简称：仁和药业 公告编号：2022-042 仁和药业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 仁和药业股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|-------------- ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[24] - Net profit attributable to shareholders reached 200 million RMB, up 10% compared to the same period last year[24] - The company's operating revenue for the reporting period was ¥2,561,096,047.49, representing a 6.60% increase compared to the previous year's adjusted revenue of ¥2,402,485,157.88[31] - The net profit attributable to shareholders was ¥299,965,510.62, a decrease of 9.66% from the previous year's adjusted net profit of ¥332,050,284.37[31] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥276,512,614.40, down 14.35% from the previous year's adjusted figure of ¥322,839,215.33[31] - The net cash flow from operating activities was ¥176,240,842.03, a decline of 9.41% compared to the previous year's adjusted cash flow of ¥194,551,978.77[31] - The basic earnings per share were ¥0.2143, down 9.65% from the previous year's adjusted earnings per share of ¥0.2372[31] - Future guidance estimates a revenue growth of 12% for the second half of 2022, supported by new product launches and market expansion efforts[24] Market Expansion and Product Development - The company plans to expand its market presence by increasing distribution channels by 20% in the next year[24] - The company has launched two new products in the health supplement category, contributing to a 5% increase in sales volume[24] - User data indicates a 30% increase in online sales, driven by enhanced digital marketing strategies[24] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[24] - The company is focused on expanding its product offerings in the pharmaceutical sector, including new formulations and therapeutic areas[41] Research and Development - Research and development expenses accounted for 8% of total revenue, reflecting the company's commitment to innovation[24] - Research and development investment was ¥29,026,567.19, showing a slight increase of 1.09% compared to ¥28,714,012.72 in the previous year[58] Financial Management and Investments - The company reported non-recurring gains totaling ¥23,452,896.22 for the period[37] - The total investment during the reporting period was ¥850,000, a decrease of 39.28% compared to ¥1,400,000 in the same period last year[74] - The total amount of funds raised was CNY 82,288,910, with CNY 35,964,380 used by the end of the reporting period, leaving a balance of CNY 46,324,530[84] - The total amount of self-raised funds replaced by the company for the industrial hemp project and other projects is CNY 71,279,533.84[92] - The company has not engaged in any derivative investments during the reporting period[81] Environmental and Social Responsibility - The company has established a 100-ton emergency pool and has developed feasible emergency plans for environmental incidents[121] - The wastewater treatment system has a designed capacity of 1,500 tons per day, and the treated wastewater meets the discharge standards[120] - The company has committed to environmental protection by increasing investments in pollution prevention, resource conservation, and ecological protection[133] - The company donated RMB 2.45 million to the Red Cross Society in Zhangshu City for purchasing and modifying 18 ambulances to support pandemic prevention and medical rescue efforts[134] - The company emphasizes employee development and has implemented a comprehensive human resources management system, including training and health safety awareness programs[133] Corporate Governance and Compliance - The company has implemented measures to improve corporate governance and investor relations, ensuring the protection of shareholders' rights[130] - The company has not reported any issues or other situations regarding the use and disclosure of raised funds[92] - The company has adhered to all relevant commitments regarding related party transactions and has ensured independence in operations and finances[141] Shareholder Information - The largest shareholder, Renhe Group, holds 23.24% of the shares, totaling 325,299,386 shares[181] - The second-largest shareholder, Yang Xiao, holds 5.49% of the shares, totaling 76,802,500 shares[181] - The employee stock ownership plan includes 262 employees holding a total of 20,380,000 shares, representing 1.45% of the company's total equity[115] - The company has not issued any new shares or conducted any share buybacks during the reporting period[181]

证券代码：000650 证券简称：仁和药业 公告编号：2022-029 仁和药业股份有限公司 关于参加 2022 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，仁和药业股份有限公司 (以下简称 "公司")将参加由江西省上市公司协会联合深圳市全景网络有限公司举办的主 题为"伴行投资者,共筑高质量发展 "江西上市公司2022年投资者集体接待日 活动，现将有关事项公告如下： 本次活动将在深圳市全景网络有限公司提供的网上平台，采取网络远程的方 式举行，投资者可以登录"全景路演"网站 (http://rs.p5w.net)或关注微信公 众号：全景财经或下载全景路演APP，参与公司本次投资者集体接待日活动，活 动时间为2022年5月27日 15:00-16:30。 届时公司的董事长、财务总监、董事会秘书将通过网络在线交流形式与投资 者就2021年年报、公司治理、发展战略、经营状况、融资计划、股权激励和可持 续发展等投资者关注的问题进行沟通。欢迎广大投资者积极参与。 特此公告 | --- | --- | ...

仁和药业股份有限公司 2022 年第一季度报告全文 证券代码：000650 证券简称：仁和药业 公告编号：2022-024 仁和药业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------|---------------------------------|------------ ...